Citadel Advisors
XENE icon

Citadel Advisors’s Xenon Pharmaceuticals XENE Stock Holding History

Citadel Advisors’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.32M Sell
38,400
-64,000
-63% -$3.55M ﹤0.01% 6233
2026
Q1 		$5.95M Buy
102,400
+40,800
+66% +$1.88M ﹤0.01% 4050
2025
Q4 		$2.76M Buy
61,600
+39,300
+176% +$1.65M ﹤0.01% 5325
2025
Q3 		$895K Buy
22,300
+900
+4% +$31.7K ﹤0.01% 7768
2025
Q2 		$670K Buy
21,400
+13,700
+178% +$447K ﹤0.01% 7940
2025
Q1 		$258K Sell
7,700
-7,000
-48% -$266K ﹤0.01% 9916
2024
Q4 		$576K Sell
14,700
-2,100
-13% -$86.8K ﹤0.01% 8249
2024
Q3 		$661K Sell
16,800
-15,000
-47% -$605K ﹤0.01% 7669
2024
Q2 		$1.24M Buy
31,800
+20,500
+181% +$819K ﹤0.01% 6180
2024
Q1 		$486K Sell
11,300
-5,600
-33% -$258K ﹤0.01% 8464
2023
Q4 		$778K Sell
16,900
-3,700
-18% -$131K ﹤0.01% 7190
2023
Q3 		$704K Buy
20,600
+6,900
+50% +$258K ﹤0.01% 7326
2023
Q2 		$527K Sell
13,700
-24,900
-65% -$990K ﹤0.01% 7826
2023
Q1 		$1.38M Buy
38,600
+8,600
+29% +$318K ﹤0.01% 6079
2022
Q4 		$1.18M Buy
30,000
+19,600
+188% +$714K ﹤0.01% 6490
2022
Q3 		$375K Sell
10,400
-1,400
-12% -$50.3K ﹤0.01% 9091
2022
Q2 		$359K Buy
+11,800
New +$357K ﹤0.01% 9402
2022
Q1 		– Sell
-37,200
Closed -$1.16M – 14716
2021
Q4 		$1.16M Sell
37,200
-233,000
-86% -$6.96M ﹤0.01% 7578
2021
Q3 		$4.13M Buy
+270,200
New +$4.7M ﹤0.01% 4678

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Citadel Advisors's XENE Position: Q2 2026 in Review

Citadel Advisors reduced its Xenon Pharmaceuticals (XENE) stake by 47% in Q2 2026, selling an estimated $69.5M and leaving 1,401,242 shares worth $84.6M. The position accounts for 0.01% of the portfolio, ranked #1108.

Citadel Advisors first reported a position in XENE in Q3 2018 and has held it in 32 quarters since. The position peaked at $154M in Q1 2026. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Citadel Advisors held 1,401,242 shares of Xenon Pharmaceuticals worth $84.6M as of Q2 2026.
  • Citadel Advisors sold 1,251,748 Xenon Pharmaceuticals shares in Q2 2026, an estimated $69.5M.
  • Xenon Pharmaceuticals made up 0.01% of Citadel Advisors's portfolio in Q2 2026, its #1108 holding.
  • Citadel Advisors first reported a position in Xenon Pharmaceuticals in Q3 2018 and has held it in 32 quarters since.
  • Citadel Advisors's Xenon Pharmaceuticals position peaked at $154M in Q1 2026.
  • 315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.